Answers are grounded in this paper and cite their sources.
Decorin mitigates fibrosis by docking onto transforming growth factor-β1 (TGF-β1), but its dense glycosylation and disulfide-rich caps hinder scalable manufacturing. Here we present miniDec, a 15-kDa decorin mimetic built from leucine-rich repeats 4–6 with newly designed, cysteine-free terminal caps. The aglycosylated construct folds efficiently in E. coli , yields >25 mg L⁻¹ after a two-step purification, and binds TGF-β1 with low-nanomolar affinity. miniDec blocks TGF-β-driven transdifferentiation of human corneal fibroblasts and, when applied topically, reduces corneal opacity, restores corneal surface regularity and accelerates epithelial wound closure in a mouse alkali-burn model, with efficacy comparable to that of full-length decorin at the fixed topical doses tested. The protein is non-cytotoxic to corneal epithelium and stromal cells. This new scaffold overcomes the production hurdles of the native proteoglycan while retaining its anti-fibrotic activity, establishing that decorin’s glycosaminoglycan chain, N-glycans and disulfide-bonded caps are dispensable for anti-fibrotic function in the cornea, and providing a manufacturable route to decorin-based therapy for corneal fibrosis.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: